Different structural remodelling in atrial fibrillation with different types of mitral valvular diseases

Europace

Volumn 12, Issue 3, 2010, Pages 371-377

  Qian, Yongjun ^a   Meng, Jun ^a   Tang, Hong ^a   Yang, Guo ^b   Deng, Yiling ^b   Wei, Dongming ^a   Xiang, Bo ^a   Xiao, Xijun ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

Atrial fibrillation; Fibrosis; Mitral valvular disease; Structural remodelling

Indexed keywords

COLLAGEN TYPE 1; COLLAGEN TYPE 3; GELATINASE A; GELATINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADULT; ARTICLE; CLINICAL ARTICLE; ELECTRON MICROSCOPE; ELECTRON MICROSCOPY; FEMALE; HEART ATRIUM FIBRILLATION; HEART LEFT ATRIUM; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART RHYTHM; HEART VENTRICLE REMODELING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MASSON TRICHROME STAINING; MITRAL VALVE DISEASE; MITRAL VALVE REGURGITATION; MITRAL VALVE REPLACEMENT; MITRAL VALVE STENOSIS; PRIORITY JOURNAL; RISK ASSESSMENT; SARCOMERE; SINUS RHYTHM; STAINING; ULTRASTRUCTURE;

ADULT; ATRIAL APPENDAGE; ATRIAL FIBRILLATION; BIOPSY; COLLAGEN TYPE I; COLLAGEN TYPE III; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICROSCOPY, ELECTRON; MIDDLE AGED; MITRAL VALVE STENOSIS; RISK FACTORS; STAINING AND LABELING; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 77749310198     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/eup438     Document Type: Article

References (20)

1. Burstein B, Nattel S. Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. J Am Coll Cardiol 2008;51:802-9.
2. Zhang S. Atrial fibrillation in mainland China: epidemiology and current management. Heart 2009;95:1052-5.
3. Truter SL, Catanzaro DF, Supino PG, Gupta A, Carter J, Herrold EM et al. Differential expression of matrix metalloproteinases and tissue inhibitors and extracellular matrix remodeling in aortic regurgitate hearts. Cardiology 2009;113: 161-8.
4. Climent V, Marin F, Mainar L, Roldán V, García A, Martínez JG et al. Influence of electrical cardioversion on inflammation and indexes ofstructural remodeling, in persistent atrial fibrillation. Int J Cardiol 2009;132:227-32.
5. Wang J, Xu R, Lin F, Zhang S, Zhang G, Hu S et al. MicroRNA: novel regulators involved in the remodeling and reverse remodeling of the heart. Cardiology 2009; 113:81-8.
6. Diker E, Aydogdu S, Ozdemir M, Kural T, Polat K, Cehreli S et al. Prevalence and predictors of atrial fibrillation in rheumatic heart disease. Am J Cardiol 1996;77: 96-8.
7. Schwartz R, Myerson RM, Lawrence T, Nichols HT. Mitral stenosis, massive pulmonary hemorrhage, and emergency valve replacement. N Eng J Med 1966;275: 755-88.
8. Goette A, Juenemann G, Peters B, Klein HU, Roessner A, Huth C et al. Determinants and consequences of atrial fibrosis in patients undergoing open heart surgery. Cardiovasc Res 2002;54:390-6.
9. Nattel S, Burstein B, Dobrev D. Atrial remodeling and atrial fibrillation: mechanisms and implications. Circ Arrhythmia Electrophysiol 2008;1:62-73.
10. Li JY, Lai YJ, Yeh HI, Chen CL, Sun S, Wu SJ et al. Atrial gap junctions, NF-kappaB and fibrosis in patients undergoing coronary artery bypass surgery: the relationship with postoperative atrial fibrillation. Cardiology 2009;112:81-8.
11. Bishop JE. Regulation of cardiovascular collagen deposition by mechanical forces. Mol Med Today 1998;4:69-75.
12. Polyakova V, Miyagawa S, Szalay Z, Risteli J, Kostin S. Atrial extracellular matrix remodelling in patients with atrial fibrillation. J Cell Mol Med 2008;12:189-208.
13. Thomas L, Mckay T, Byth K. Abnormalities of left function after cardioversion: an atrial strain rate study. Heart 2007;93:89-95.
14. Li YY, Feldman AM, Sun Y, McTiernan CF. Differential expression of tissue inhibitors of metalloproteinases in the failing human heart. Circulation 1998;98: 1728-34.
15. Nakano Y, Niida S, Dote K, Takenaka S, Hirao H, Miura F et al. Matrix metalloproteinase-9 contributes to human atrial remodeling during atrial fibrillation. J Am Coll Cardiol 2004;43:818-25.
16. Xu J, Cui G, Esmailian F, Plunkett M, Marelli D, Ardehali A et al. Atrial extracellular matrix remodeling and the maintenance of atrial fibrillation. Circulation 2004;109: 363-8.
17. Bailey GW, Braniff BA, Hancock EW, Cohn KE. Relation of left atrial pathology to atrial fibrillation in mitral valvular disease. Ann Intern Med 1968;69:13-20.
18. Mary-Rabine L, Albert A, Pham TD, Hordof A, Fenoglio JJ Jr, Malm JR. The relationship of human atrial cellular electrophysiology to clinical function and ultrastructure. Circ Res 1983;52:188-99.
19. Kaireviciute D, Aidietis A, Lip GY. Atrial fibrillation following cardiac surgery: clinical features and preventative strategies. Eur Heart J 2009;30:410-25.
20. Nicolazzo P. Stenoitc valvular disorders. In Williams JP (ed). Postoperative Management of the Cardiac Surgical Patient. 1st ed. New York: Churchill Livingstone; 1996. p37.